A recent review reveals how aberrantly reprogrammed purine metabolism acts as a critical driver of tumor progression and therapy resistance. By comprehensively mapping the regulatory networks of key metabolic enzymes and their inhibitors, the study highlights the selective targeting of purine metabolism networks as a powerful next-generation anticancer strategy.
Cancer cells possess an insatiable appetite for nucleotides to support their rapid division, survival under stress, and evasion of the immune system. In a recent review published in Advanced Cancer Research, researchers provide a comprehensive framework on how purine metabolism—a fundamental pathway governing nucleic acid synthesis, energy supply, and cellular signaling—is hijacked by tumors to drive malignancy.
Rather than viewing purine metabolism merely as a passive supply chain for DNA and RNA, the authors demonstrate that key enzymes within this network (such as PRPS, IMPDH, and ADA) act as active, multifunctional drivers of tumorigenesis. The review systematically summarizes the dysregulation across all three major components of purine metabolism: de novo biosynthesis, the salvage pathway, and purine catabolism. Furthermore, the paper evaluates the latest advances in small-molecule inhibitors targeting these crucial enzymes, assessing their therapeutic potential and clinical application prospects.
Key highlights include:
Metabolic Reprogramming: Purine metabolism is aberrantly reprogrammed across multiple cancers to sustain hyperproliferation and metabolic adaptation.
Crucial Drivers: Key purine metabolic enzymes actively connect nucleotide synthesis with tumor progression, immune microenvironment remodeling, and therapy resistance.
Next-Generation Therapeutics: Selective pharmacological targeting of these metabolic hubs—alone or in combination with other therapies—presents a highly promising next-generation anticancer strategy.
The review further notes that while targeting cancer metabolism is conceptually compelling, challenges such as tumor-microenvironment interactions, metabolic heterogeneity, and adaptive resistance remain. The authors emphasize that future research integrating single-cell sequencing and spatial multi-omics will help map precise metabolic regulatory networks, paving the way for the development of highly selective, low-toxicity inhibitors.
This work provides a comprehensive roadmap for understanding purine metabolic reprogramming, positioning it not just as a consequence of cancer, but as a critical vulnerability and a prime target for future personalized therapeutic interventions.
Citation: Tang R, Zhu M, Wu Y, Wang S, Song M. Targeting purine metabolism as the next generation of cancer therapeutic strategies. Adv. Cancer Res. 2026(2):0010, https://doi.org/10.55092/acr20260010 .
Advanced Cancer Research
Literature review
Not applicable
Targeting purine metabolism as the next generation of cancer therapeutic strategies
14-Aug-2026